# First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/first-in-human-phase-i-study-of-pictilisib-gdc-0941-a-potent-pan-class-i/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Debashis Sarker,Joo Ern Ang,Richard D. Baird,Rebecca Kristeleit,Krunal Shah,Víctor Moreno,Paul A. Clarke,Florence I. Raynaud,Gallia G. Levy,Joseph A. Ware,Kathryn Mazina,Ray Lin,Jenny Wu,Jill Fredrickson,Jill M. Spoerke,Mark R. Lackner,Yibing Yan,Lori S. Friedman,Stan B. Kaye,Mika K. Derynck,Paul Workman,Johann S. de Bono |
| Citations | 362 |
| DOI | 10.1158/1078-0432.ccr-14-0947 |
| Fields | Biochemistry, Genetics and Molecular Biology |
| Open Access | true |
| OA Status | bronze |
| OA URL | https://clincancerres.aacrjournals.org/content/clincanres/21/1/77.full.pdf |
| OpenAlex ID | https://openalex.org/W2128855114 |
| PMID | 25370471 |
| Type | article |
| Year | 2014 |

## Paper authors

- [Rebecca Kristeleit](https://scholariq.org/researchers/rebecca-kristeleit/)
- [Johann S. de Bono](https://scholariq.org/researchers/johann-s-de-bono/)

## Paper journal

- [Clinical Cancer Research](https://scholariq.org/journals/clinical-cancer-research/)

## Paper primary topic

- [PI3K/AKT/mTOR signaling in cancer](https://scholariq.org/topics/pi3k-akt-mtor-signaling-in-cancer/)

## Paper topics

- [PI3K/AKT/mTOR signaling in cancer](https://scholariq.org/topics/pi3k-akt-mtor-signaling-in-cancer/)
- [Protein Degradation and Inhibitors](https://scholariq.org/topics/protein-degradation-and-inhibitors/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.